Japan Digital PCR (dPCR) and Real-Time PCR (qPCR) Market Growth, Size, Share, Industry Report and Forecast 2019-2025

Japan digital PCR (dPCR) and real-time PCR (qPCR) market is expected to grow at a CAGR of 8.2% during the forecast period. Japan has a significant growth in the dPCR and qPCR market owing to the increase in the prevalence of infectious disease and development in healthcare infrastructure. Among major global economies, Japan has the highest percentage of the geriatric population. Various cancers are more commonly found in the elderly age group. For instance, colon cancer accounts for more than 90% of individuals diagnosed over the age of 50. Similarly, stomach cancer accounts for about 60% of those diagnosed are over the age of 60. Cancer is one of the leading causes of death in Japan and the mortality rate is increasing since the last 30 years in the country as per the Japanese government. For instance, according to the World Health Organization (WHO), Japan recorded 883,395 new cancer cases in 2018. This leads to the adoption of dPCR and qPCr-based assays to detect mutations in a DNA region that is associated with many cancer types.

To Request a Sample of our Report on Japan Digital PCR (dPCR) and Real-Time PCR (qPCR) Market: https://www.omrglobal.com/request-sample/japan-digital-pcr-and-real-time-pcr-market

The presence of some crucial players such as Takara Bio, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., and among others is estimated to be some of the major factors that are propelling the growth of the market. Further, strategic initiatives of players such as mergers, acquisitions, and product launches are also estimated to contribute towards the growth of the market. For instance, in January 2019, Abbott Laboratories announced that it has entered into an eight-year partnership agreement with the Japanese Red Cross Society (JRC). Under this agreement, Abbott is an exclusive supplier of serological instrumentation, tests, and consumables used for blood and plasma screening in Japan. The JRC screens approximately 5 million blood donations each year enabling ensure a safe supply of products needed for blood transfusions and plasma therapies. Abbott's broad portfolio of products is used to screen more than 60% of the world's blood and plasma supply. This development aids Abbott to strengthen its position and increase its revenue base in the Japanese market.

(Get 15% Discount on Buying this Report)

A full Report of Japan Digital PCR (dPCR) and Real-Time PCR (qPCR) Market is Available at: https://www.omrglobal.com/industry-reports/japan-digital-pcr-and-real-time-pcr-market

Japan dPCR and qPCR Market Segmentation

By Technology

· Quantitative PCR (qPCR)

· Digital PCR (dPCR)

By Product

· Reagents and Consumables

· Instruments

· Software

By Application

· Research Application

· Clinical Application

· Forensic Application

Company Profiles

· Abbott Laboratories, Inc.

· Agilent Technologies, Inc.

· BioMérieux S.A.

· Bio-Rad Laboratories, Inc.

· Eppendorf AG

· JN Medsys

· Promega Corp.

· Qiagen N.V.

· Takara Bio Inc.

· Thermo Fisher Scientific Inc.

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/japan-digital-pcr-and-real-time-pcr-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.